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and implement a Quality Improvement (QI) project
addressing the process for administration and drug moni-
toring for patients receiving these drugs by implementing
the Institute for Healthcare Improvement (IHI) model for QI.
The IHI model utilizes the Plan-Do-Study-Act process in
which a series of small tests of change are implanted to
achieve desired results. The team established the standard
nursing practice as administration of tacrolimus or cyclo-
sporine through the white lumen of the tunneled CVC and
lab draws for drug monitoring through the red lumen of the
tunneled CVC. BMT nurses were informed of the new stan-
dard practice during twice daily safety huddles. Nurses were
instructed to remember the standard as “red for blood”
meaning to draw from the red lumen. Since implantation of
this standard practice there have been zero reported line
contaminations.499
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Background: Hemorrhagic cystitis is a complication that
may arise following Stem Cell Transplantation (SCT) as
a result of bladder inﬂammation, injury, and clot formation
that may progress to renal failure. It occurs in approximately
30 percent of SCT patients as a result of the toxic effects of
antineoplastic alkalinic agents including Cyclophosphamide,
Ifosphamide, Busulfan, immunosuppressant therapy, radia-
tion therapy, graft versus host disease (GVHD), and viral,
bacterial, and fungal infections. The treatment of choice for
hemorrhagic cystitis is continuous bladder irrigation (CBI) to
instill solutions and medications directly into the bladder.
Nursing interventions during CBI require extensive knowl-
edge about the disease and multiple conditions that cause
bladder hemorrhage. Currently, there is no formal training
program about CBI for nurses on the SCT unit; nursing staff
obtain bladder irrigation information from guidelines avail-
able from the institutional intranet website and from peers.
Purpose: The purpose of this project is to prepare new
nurses in the SCT unit to provide evidence-based care for
patients experiencing CBI treatment, to educate them on the
etiology of hemorrhagic cystitis treatments used to aid in the
healing of the bladder, and to prevent or intervene when
complications arise. Recently, a need for education was
identiﬁed due to a surge of new nursing staff hired to the SCT
unit.
Intervention: The clinical educator developed an educa-
tional program consisting of four modules about managing
patients with hemorrhagic cystitis with CBI for nurses in the
SCT unit. Malcolm Knowles’ theory of andragogy was used to
guide the program as it considers needs educators must
address when teaching an adult audience.
Results/Evaluation: A post-test was administered at the end
of the CBI educational program to evaluate knowledge
improvement and program evaluation. The CBI educational
program will also be included as part of the annual SCT staff
competency and added to orientation program for the new
SCT nurse.
Discussion: Nurses in SCT units need to be vigilant for
complications such as hemorrhagic cystitis. Development ofsuch educational programs improves nursing knowledge and
strengthens clinical practice in an area that requires expert
nursing care to support positive patient outcomes.500
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The 2006 Census estimates that the total Aboriginal
Australian population is 458,520 which is 2.4% of Australia's
population. As with other indigenous peoples worldwide
this population has been shown to have unique and signiﬁ-
cant health requirements. These necessitate cohesive part-
nerships between the health care teams and the Aboriginal
people to further improve health outcomes. Much of the
literature about health needs of Aboriginal Australians is
concerning primary health care. There is a paucity of
evidence surrounding the management of Aboriginal people
undergoing a Hematopoietic Progenitor Cell (HPC) trans-
plant, including identiﬁcation of suitable donors and
appropriate therapeutic medical management.
Currently there are few donors who identify themselves
as of Aboriginal descent. The powerful ethnic bias in the
European, North American and Australian bone marrow
registries towards northern Caucasian descent hinders the
identiﬁcation of suitably matched donors. In an attempt to
address the deﬁciency of suitable donors for the Aboriginal
person, the Sydney Cord blood bank developed an initiative
to collect cord blood units in regional and rural areas to
increase the cord blood units collectedwith the unique tissue
typing found in Aboriginal people.
The difﬁculties in donor identiﬁcation and increased
transplant complications were evident when a 17 year old
Aboriginal man presented with secondary acute myeloid
leukaemia requiring HPC transplant. The search process will
be discussed, speciﬁcally addressing the complexities in
identifying a suitable donor and the unique pharmacoki-
netics in Aboriginal people which may change the efﬁcacy
and toxicity proﬁle of commonly prescribed medications.
Throughout the transplant timeline the HPC team inte-
grated the principals of cultural safety when managing this
young Aboriginal man and his family. This was achieved by
recognising the principles of awareness, safety and security
unique to Aboriginal Australians.501
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An allogeneic bone marrow transplant offers potentially
curative therapy to patients with leukemia, lymphoma,
multiple myeloma, and myelodyspastic syndrome. Identiﬁ-
cation of a human leukocyte antigenmatched donor, through
a standardized screening process, is an essential component
of the allogeneic transplant. At this transplant center, nurse
